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Abstract 
Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, re-
sistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired re-
sistance). At present, resistance is usually diagnosed during treatment after a long period of 
drug administration.  
In the present paper, methods for a rapid assessment of drug resistance are described. Three 
main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture 
tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods 
are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. 
Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture 
tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for 
which great potential has been predicted, are largely still in the development stage. Individual 
resistance surveillance with tests delivering rapid results signifies progress in cancer therapy 
management, by providing the possibility to avoid drug therapies that are ineffective and only 
harmful. 
Key words: cancer drug resistance, in vitro cancer drug resistance tests,  in  vivo  cancer  drug  re-
sistance tests, cancer biomarker tests 
Introduction 
Since the beginning of cancer chemotherapy the 
frequent  lack  of  drug  response  in  solid  tumors  has 
been a major problem. The main cause of failure to 
respond  to  cytostatics  is  drug  resistance.  In  nearly 
50% of all cancer cases, resistance  to chemotherapy 
already exists before drug treatment starts (intrinsic 
resistance), and in a large proportion of the remaining 
half  resistance  develops  during  treatment  (acquired 
resistance)  [1].  All  efforts  to  overcome  resistance  to 
chemotherapy so far have failed, owing to the enor-
mous  heterogeneity  and  complex  biology  of  cancer 
cells, with wide individual variations [2]. Meanwhile, 
the knowledge of various resistance mechanisms has 
increased over the years [3], leading to the develop-
ment of new drugs that can be specifically targeted. 
However, the new "targeted" drugs also suffer from a 
considerable  failure  rate  and  from  toxicity  [4].  The 
increasing number of new anticancer drugs has not 
efficiently reduced the occurrence of drug resistance 
up to now.  
Diagnosis  of  drug  resistance  in  individual  pa-
tients would improve cancer treatment by the avoid-
ance of inefficient treatment. The aim of the present 
paper is to discuss the possibilities for realizing this 
goal.  The  following  three  methods  are  available  to 
assess cancer drug resistance: fresh tumor cell culture 
assays, cancer biomarker tests, and positron emission 
tomography tests.  Int. J. Med. Sci. 2011, 8 
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Fresh tumor cell culture tests  
As early as the 1950s, research teams started to 
develop  laboratory  tests  in  order  to  predict  tumor 
reaction to cytostatic drugs [5]. They used fresh cancer 
tissue and examined the effect of the drugs on tumor 
cell growth. At the beginning laboratory techniques 
were still in their infancy. Short term cell cultures of 
cancer  tissues  were  difficult  to  perform  and  proce-
dures varied from laboratory to laboratory. However, 
the  cancer  cell  assays  were,  thanks  to  better  tech-
niques,  continuously  improved  over  the  last  few 
decades and brought to a certain perfection. There are 
two steps in the preparation of the tests, first the fresh 
cell  culturing  and  then,  when  this  is  successful  the 
examination of the drug effect. Cell cultures in medi-
cine  are  now  established  laboratory  tools.  Whereas 
immortalized cancer cell lines used for research pur-
poses have lost a large part of individual tumor char-
acteristics  the  preparation  of  fresh  tumor  tissue  is 
necessary  in  order  to  obtain  cancer  cells  with  still 
highly  preserved  individual  tumor  properties  [6]. 
Special arrangements have to be made before the bi-
opsy is taken by the oncologist to garantee a rapid and 
safe transport of the probe i.e. a specialized laboratory 
must  be  contacted,  the  means  of  transport  and 
transport medium arranged and precaution taken that 
the probe is immediately placed in the transportme-
dium.  Extensive  descriptions  of  special  laboratory 
techniques  for  fresh  cancer  cell  cultures  are  now 
available  [7,  8].  The  cell  preparation  may  vary  de-
pending  on  the  tumor  type  in  test.  Table  1  shows 
frequently tested tumor types for which special cell 
preparations were published [9-27]. For the examina-
tion of the drug effect after incubation several meth-
ods are in use. In the 1970s the method of measuring 
the thymidine incorporation into cancer cell DNA [28] 
was developed by one of us (M.V.). It estimates the 
inhibitory effect on cell growth. This technique as well 
as some others have found their way into laboratory 
practice. Fig. 1 is a schematic illustration of the pro-
cedure of fresh tumor cell culture assays. Although 
various  assays  have  been  developed,  the  principal 
steps,  i.e.  isolation  of  cells,  incubation  of  cells  with 
drugs and assessment of cell survival are the same. 
Usually a range of drug doses is applied in order to 
find  a  dose-response  relationship.  Drug  concentra-
tions in the tests are similar to drug concentrations 
usually found in-vivo during treatment. All methods 
measure molecular processes of cancer cells, revealing 
cell activity and thus indicating cell growth or death 
[29, 30]. Frequently used methods are the thymidine 
incorporation into cell DNA [31] and the loss of cell 
ATP  [32].  Drug  resistance  can  be  recognized  by  no 
decrease  of  thymidine  uptake  into  cell  DNA  or  no 
decrease of cell ATP. Fresh tumor cell culture assays 
are  applicable  to  many  types  of  cancer,  since  they 
register the integral cell reaction. The predictive value 
of the assays, depending  on cancer tissue, which is 
usually  only  available  before  treatment,  consists  in 
indicating intrinsic resistance.  
 
 
Table 1. Tumor types for which short term primary cell cultures are used to test tumor response to cancer drug therapy.  
  Tumor 
 
References 
 
Colorectal cancer  Paraskeva C et al [9], Park J-G et al [10], Whitehead [11] 
Testicular Cancer  Pera MF [12] 
Skin cancer  Parkinson EK et al [13], Halaban R [14] 
Lung cancer  Twentyman PR [15], WU R [16] 
Brain cancer  Darling JL [17] 
Ovarian cancer  Whelan RDH et al [18], Wilson AP [19] 
Prostate cancer  Harper ME [20], Bright RK et al [21] 
Breast cancer  O’Hare MJ [22], Speirs V [23] 
Cervical cancer  Stern P et al [24] 
Bladder cancer  Fu VX et al [25] 
Head and neck cancer  Edington KG et al [26] 
Pancreatic cancer  Iguchi H [27] 
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Fig. 1. Schematic procedure of fresh tumor cell culture assays. 
 
 
None of the tests developed has been adopted so 
far in clinical routine practice, mainly because of the 
lack  of  general  recognition.  Critical  comments  pub-
lished  in  the  renowned  New  England  Journal  of 
Medicine  in  the  1980s  [33]  on  test  artefacts  causing 
false results dramatically reduced interest in further 
research. The verdict which arose then that assays for 
drug response are unreliable is still widely accepted. 
This  opinion  ignores  the  fact  that  assay  techniques 
have improved and that test results of drug resistance 
and  drug  sensitivity  should  not  be  confused:  drug 
resistance is considered as highly predictable, which 
is not the case with drug sensitivity. Results of sensi-
tive drugs obtained by the net effect of drug action on 
cancer cells are not very reliably, since many steps in 
the body are required to reach the target. However, 
their effectivity may be increased by the fact that cases 
of ineffective drugs can be eliminated [34].  
With the recent recognition, that cancer therapy 
can be optimized by personalized i.e. individualized 
drug treatment, interest has again arisen in fresh tu-
mor cell culture assays. Recently ASCO felt induced to 
publish  an  assessment  of  the  assays  reviewing  the 
literature [35]. It came to the conclusion that the tests 
are still investigational but asserted that an in-vitro 
approach  has  great  potential  to  spare  patients  the 
morbidity of ineffective chemotherapy regimens. The 
ASCO judgment was criticized for the fact that only 12 
studies were taken for the evaluation and that no dis-
tinction was made between sensitivity and resistance 
results. Many studies, showing good correlation be-
tween  in-vitro  resistance  with  in-vivo  outcome  re-
mained unnoticed [36]. In the 1980s a review, cover-
ing 27 studies already showed excellent correlations 
in  different  chemotherapy-treated  tumor  types 
(>90%) [37]. Similar correlations were found in other 
comprehensive  reviews  [34,  38].  In  the  meantime 
many  more  studies  on  different  tumor  types  have 
been  published,  some  with  variable  results.  It  has 
been  pointed  out  that  the  labor-intensive  assays 
should  only  be  carried  out  by  experienced,  highly 
specialized laboratories. Standardization of the tests 
would make it easier to compare the results of dif-
ferent studies. 
 Ovarian cancer is now one of the best investi-
gated  cancer  types  with  promising  results  for  indi-
vidualized assay-assisted chemotherapies. In a recent 
review  earlier  results  have  been  corroborated,  i.e. 
most tumor response tests showed excellent correla-
tion with clinical resistance but varied in their ability 
to  predict  sensitivity  [39].  Another  recent  study 
demonstrated  that  assay-assisted  chemotherapy  in 
ovarian cancer may result in reduced costs compared 
to empiric therapy [40]. A novelty may be added here: 
the  National  Comprehensive  Cancer  Network 
(NCCN)  in  the  USA  [41],  which  provides  “Clinical 
Practice Guidelines for Oncology” mentioned chem-
otherapy-resistance assays for the first time in a recent 
update on ovarian cancer treatment (2010). It declared 
that such tests are being used in some NCCN centers 
to aid in selecting chemotherapy in situations where 
there are multiple equivalent chemotherapy options 
available. In another recent publication [42], discuss-
ing  the  question  of  chemosensitivity  testing  for  ad-Int. J. Med. Sci. 2011, 8 
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vanced gastric cancer, it was cited that pre-treatment 
testing is already approved by the Japanese Ministry 
of Health in 11 institutes. This shows that interest in 
further research on fresh tumor cell culture assays has 
now considerably increased.  
In-vitro diagnosis of drug resistance has not only 
been carried out on solid tumors; it has been demon-
strated  that  patients  with  haematological  neoplastic 
diseases can also profit [43]. Recent publications cer-
tify the usefulness of such assays in the rapid recog-
nition of resistance which allows treatment modifica-
tion shortly after [44, 45].  
Cancer biomarker tests 
Tumor markers - also called cancer biomarkers - 
already  attracted  attention  as  diagnostic  tools  for 
cancer detection and  growth indicators early in the 
last century [46]. The search concentrated on specific 
cancer-derived  molecules  occurring  in  the  blood. 
Several markers, such as the carcinoembryonic anti-
gen (CEA) and alpha-fetoprotein (AFP), found their 
way at an early stage into clinical laboratories. Many 
others have followed in the meantime. However, most 
of them are not tumor specific. The use of changes of 
serum  markers  as  a  measure  of  tumor  response  to 
therapy  seems  appealing  because  it  is  non-invasive 
and  can  be  frequently  repeated.  No  special  efforts 
have been made so far to carry out studies to investi-
gate their practical value for this purpose. Only a few 
tumor markers were used in clinical trials e.g. pros-
tate-specific antigen (PSA) in prostate cancer, CA 125 
in ovarian cancer, thyroglobulin in thyroid cancer and 
human  chorionic  gonadotropin  (HCG)  in  chori-
onepithelioma. In these cases it has been shown that 
the  markers  fell  to  very  low  levels  after  successful 
treatment. However, it is still not known to what ex-
tent  markers  can  reliably  reflect  the  viable  tumor 
mass. The pathobiology of tumor markers is still not 
well understood. It remains hard to understand why 
tumor markers have not been investigated to a greater 
degree in the huge number of previous chemotherapy 
studies.  
Only  recently  have  cancer  biomarkers  gained 
wider  recognition.  The  American  National  Cancer 
Institute  launched  the  project  “Early  Detection  Re-
search  Network”  (EDRN)  as  a  new  field  of  cancer 
research, focused on identifying markers both for the 
early detection of cancer and of cancer risk. The main 
aim is creating validated biomarkers for early thera-
peutic intervention in malignant diseases [47, 48]. A 
large number of organizations are now participating 
in cancer biomarker research [49]. Unfortunately the 
program does not engage in investigation of markers 
for drug response testing.  
The pharmaceutical industry now uses overex-
pressed  growth  factors,  i.e.  their  cell  receptors  as 
cancer biomarkers to develop new targeted anticancer 
drugs with better tumor response. However, tumor 
concentrations of growth factor receptors do not reli-
ably predict their therapeutic effect in individual cas-
es. Only in some small subgroups of patients detected 
by special biomarkers could a major therapeutic suc-
cess be demonstrated. Examples are: for trastuzumab 
breast cancer with overexpressed HER2, for imatinib 
gastrointestinal stroma cell tumor (GIST) with over-
expressed  C-kit  and  chronic  myeloid  leukaemia 
(CML) with BCR-ABL fusion protein, and for gefitinib 
and erlotinib non small cell lung cancer (NSCLC) with 
mutations in the EGFR gene [50]. Another subgroup 
which benefits from EGFR inhibitor treatment is col-
orectal cancer with Kras wild type [51]. The search for 
biomarkers to find new subgroups of cancer patients 
for treatment with targeted drugs goes on.  
Potential biomarkers for the prediction of drug 
response  are  several  proteins  which  play  a  role  in 
drug resistance mechanisms. Such cellular factors are 
resistance proteins, which can be determined by im-
munohistochemistry.  Laboratory  experiments  with 
short-term cell cultures of lung cancers have shown 
that  excellent  correlations  exist  between 
drug-resistant cells and several of the resistance pro-
teins [52]. The determination of resistance proteins in 
cancer  cell  biopsies  seems  a  feasible  way  to  detect 
intrinsic drug resistance. So far no test based on re-
sistance  protein  determination  has  been  adopted  in 
clinical practice.  
 In  a  wider  sense,  pharmacogenetics  is  part  of 
cancer biomarker research. Tests examine the influ-
ence of genetic factors on drug action. New laboratory 
techniques,  for  instance  genomics,  proteomics,  and 
transcriptomics (omics), make it possible to determine 
a great number of biological molecules whose com-
position is considered to provide information about 
the effectiveness and toxicity of drugs. Since investi-
gations using omics are dependent on cancer tissue, 
which is often only available before the commence-
ment of therapy, only intrinsic resistance can be veri-
fied. In order to detect predictive biomarkers highly 
sophisticated data analytical methods have now been 
developed.  In  Fig.  2  a  schematic  illustration  of  the 
main steps for such data analysis, algorithms for fin-
gerprint  detection  of  cancer  biomarkers,  is  shown. 
Mathematics  and  Computer  Sciences  play  an  im-
portant part in observing essential markers compar-
ing  biological  material  from  patients  with  drug  re-
sistance  with  material  from  patients  without  drug 
resistance. Algorithms have to deal not only with the 
giant  mass  of  data,  but  also  with  their  dynamic Int. J. Med. Sci. 2011, 8 
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change. Thus it is well known that an individual pro-
teome changes quite dramatically during a day, de-
pending on a variety of factors. Only a large enough 
group of patients allows to identify components that 
do  not  differ  much  between  individuals  from  the 
same group.  
 
 
Fig. 2.  Different fields with sub-areas necessary  for data 
analysis algorithms for fingerprint detection of cancer bi-
omarkers 
There  are  already  several  publications  which 
describe new biomarkers, detected by sensitive anal-
ysis algorithms. However, the clinical significance of 
these  substances,  such  as  Let-7i,  a  biomarker  for 
therapy  of  epithelial  ovarian  cancer  [53]  or  beta  III 
tubulin, a biomarker for chemoresistance in non-small 
cell lung cancer [54] has still to be proven. A recent 
review of biomarkers of chemotherapy resistance in 
breast cancer discusses the difficulties of clinical bi-
omarker  validation  [55].  Prediction  of  cancer  drug 
action with pharmacogenetic assays is still in its in-
fancy. Results still have to be judged critically, since 
misinterpretations are possible [56]. The microarrays 
used for the tests are not standardized, which makes it 
difficult  to  compare  the  results  of  different  studies 
[57].  
Positron emission tomography tests  
Diagnosis of drug resistance during drug treat-
ment  was  difficult  in  the  past.  The  only  method 
available  was  tumor  size  control.  A  solution  was 
found recently by using a nuclear medicine technique, 
positron  emission  tomography  (PET).  Already  in 
clinical use for many years for the detection of cancer 
localisation, the method can now also be applied to 
determine the metabolic activity of neoplastic tissue. 
Fig. 3 shows the schematic illustration of quantitative 
cancer image analysis in positron-emission tomogra-
phy.  
 
 
 
 
 
Fig. 3. Schematic illustration of quantitative cancer image analysis in positron-emission tomography. 
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The  tomograph  captures  dynamic  uptake  pro-
files following the radiopharmaceutical injection. The 
blood  clearance  curve,  which  serves  as  the  input 
function for kinetic modeling is obtained from blood 
pool structures in the image. Blood and tissue curves 
with a model of radiopharmaceutical kinetics are used 
to estimate parameters relevant to a particular tumor 
and its treatment. In clinical practice a more simpli-
fied and practical alternative to kinetic analysis is of-
ten used. It is termed standard uptake value (SUV) 
and defined as the radiopharmaceutical tissue uptake 
(kBq/ml) divided by the injected dose per unit patient 
weight (MBq/k). SUV has a value of 1 for uniformly 
distributed tracer and a value greater than 1 in tissues 
where the tracer accumulates. Dynamic cancer imag-
ing  is  carried  out  with  the  radiopharmacon 
18-fluoro-deoxyglucose  (18F-FDG)  which  shows  tu-
mor glycolysis as a parameter of cell activity [58, 59]. 
The FDG uptake in the tumor correlates with the rate 
of glycolysis, being more intensive in neoplastic tissue 
than  in  normal  tissue  from  which  neoplasia  arises. 
The correlation is strongest in aggressive tumor types; 
maximum values were registered in lung cancer. The 
combination  of  the  PET  camera  with  computed  to-
mography (PET/CT) allows the exact anatomical lo-
calisation  of  very  small  tumor  mass.  The  radiation 
exposure of patients is small, the half-life of 18-fluor 
only  110  minutes.  Monitoring  treatment  response 
requires  PET scans before and after the  therapeutic 
intervention. The first scan is for staging the tumor 
activity,  the  second  scan  can  show  a  therapy  effect 
after 1 or 2 drug treatment cycles. A number of studies 
carried  out  on  different  tumor  types  could  demon-
strate the potential of 18F-FDG PET to diagnose drug 
response at an early stage of treatment. Table 2 shows 
tumor types for which results are already available 
[60-66]. Generally accepted criteria for response cal-
culation, are still missing, which makes it difficult to 
compare the results of different studies. Quantifica-
tion of PET values can be affected by some technical, 
biological  and  physical  factors  which  must  be  con-
sidered in the calculations [67]. Special attention has 
also to be drawn to different pharmacological actions 
of anticancer drugs. New targeted drugs, for instance, 
which suppress cancer- induced overexpressed cellu-
lar signal transductors and thus act mainly cytostati-
cally compared with classical cytotoxic drugs require 
special timing of scans [68]. International guidelines 
for PET tests are therefore necessary to guarantee the 
quality and quantitative accuracy of the results. Nu-
merous studies are now in progress in order to make 
PET testing acceptable for routine clinical use.  
PET uses a similar principle to that of the in-vitro 
test of fresh cancer cell cultures by measuring cancer 
cell metabolic activities. However, the PET technique 
seems also to have the potential to guide therapies by 
imaging several metabolic steps in cancer cell growth; 
with the aspect to be used for diagnosing tumor drug 
resistance. The expanding development of new radi-
otracers offers the prospect that imaging may soon be 
possible  for  measuring  cellular  proliferation,  tumor 
hypoxia,  apoptosis  and  special  growth  factors  like 
steroid  receptors,  human  epidermal  growth  factor 
receptor,  vascular  endothelial  growth  factor  and 
P-glycoprotein  [69,  70].  Thus  nuclear  medicine 
methods, usable under in-vivo conditions, are likely 
to play a key role in future clinical cancer treatment. 
 
 
Table 2. Tumor types for which FDG-PET assays are used 
to assess tumor response to cancer drug therapy. 
  Tumor 
 
References 
 
  Malignant lymphoma  Hutchings M et al [60]  
  Lung cancer  Hicks RJ [61] 
  Colorectal cancer  de Geus-Oei LF et al [62] 
  Breast cancer  Avril N et al [63]  
  Cancer of the cervix  Schwarz JK et al [64] 
  Cancer of the ovaries  Schwarz JK et al [64] 
  Head and neck carcinoma  Schöder H et al [65] 
  Esophageal cancer 
 
Krause BJ et al [66] 
 
 
 
Discussion and future prospects 
Drug resistance, a hitherto unsolved pharmaco-
logical problem in cancer drug therapy, accounts for 
much useless treatment and has caused much hard-
ship to patients. Early diagnosis is therefore of crucial 
importance. Up till now oncological organisations still 
recommend, as guidelines for response assessment in 
solid tumors, anatomically based imaging. However, 
tumor size change is not a reliable sign of drug effect. 
Waiting for tumor shrinkage can postpone the diag-
nosis of drug resistance. Although methods of early 
detection were always desirable, not much effort has 
been made in past decades to support research in this 
field. Only recently has interest increased in improv-
ing drug response assessment, also in cancer clinical 
trials [71].  
Fresh cancer cell culture assays are still the only 
methods  available  to  diagnose  intrinsic  drug  re-
sistance in the individual patient. However, there may 
be some difficulty to find a specialized laboratory that 
can  carry  out  the  laborious  and  error-prone  assays 
and can guarantee reliable results. The laboratory can Int. J. Med. Sci. 2011, 8 
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help to give detailed advice for the necessary clinical 
preparations.  Patients’  information  usually  causes 
problems, because the result, intrinsic drug resistance, 
signifies  the  detection  of  ineffective  drugs,  whereas 
the  main  interest  understandably  concentrates  on 
finding  effective  drug  treatments,  which  cannot  be 
assured. It has to be made clear that the percentage of 
patients  which  do  not  profit  from  standard  chemo-
therapies is usually high and that therefore the value 
of being able to escape useless treatments can be great. 
The high cost of tests has to be considered too, yet the 
costs of drug treatment are even higher.  
When cancer treatment has been started without 
testing intrinsic resistance, it is desirable to establish 
the drug resistance situation as soon as possible. This 
is now possible with the positron-emission tomogra-
phy (PET) test described in detail above. Yet it can no 
longer be distinguished whether the failure of drug 
action  is  caused  by  an  intrinsic  or  an  acquired  re-
sistance. Acquired resistance may develop rapidly, as 
the  results  of  a  recent  in-vitro  study  with  human 
cancer cells of various types have indicated [72]. On 
account of the extensive literature supporting the use 
of  18F-FDG  PET,  this  method  has  already  found 
widespread use in clinical practice; tests are carried 
out by nuclear medicine departments. Since the test is 
clearly  superior  to  tumor  size  measurements  it  has 
already been proposed to replace the currently used 
“Response  Evaluation  Criteria  in  Solid  Tumors” 
(RESIST) based only  on anatomic imaging by “PET 
Response Criteria in Solid Tumors” (PERSIST) which 
has  no  limitation,  particularly  in  assessing  the  new 
cancer therapy which stabilizes disease [73].  
Great hope of new cancer biomarkers, now de-
tectable  by  analyzing  biological  samples  with  new 
techniques  is  curtailed  by  the  fact  that  the  host  of 
markers, which can be found makes it difficult to de-
tect suitable ones for clinical use. Markers for treatable 
subgroups of patients and for the surveillance of drug 
response during treatment are the main challenges of 
the ongoing research. Although some progress can be 
registered, reliable biomarker tests for drug resistance 
in the individual patient are still not available.  
The literature on optimizing cancer drug therapy 
by avoiding ineffective treatment is still sparse. Sup-
portive therapy without knowing the situation with 
regard to individual drug resistance is obviously not 
worth striving for.  
In a recent book Bosanquet and Sikora discuss-
ing the future of cancer care note that the continuous 
flow  of  new  and  very  expensive  therapies  also  re-
quires new treatment strategies [74]. They state that 
selecting  patients  suitable  for  chemotherapy  is  now 
possible and would help clinicians to recognize which 
localized cancers can be left alone and which tumors 
will respond to drugs. Predictive assays would dra-
matically improve the quality of life. The authors also 
add that although the technology for revealing drug 
response exists, it has to be accepted that prediction 
will  never  be  totally  accurate  and  uncertainty  will 
remain [74].  
Conclusions 
Predictive  assays  for  the  diagnosis  of  cancer 
drug resistance are now able to optimize cancer drug 
therapy by individualizing it. In the present literature 
individualized (also called personalized) therapies are 
restricted to some subgroups of patients, selected by 
biomarkers  which  promise  a  better  response.  How-
ever,  only  the  diagnosis  of  drug  resistance  in  indi-
vidual cases can exclude non-response. The long ne-
glected research on individual resistance tests needs 
to be intensified by further developments. To make 
them easier and less costly to carry out would make 
them  accessible  to  more  patients.  From  a  medical 
point  of  view  a  rethinking  of  the  pharmacological 
strategy of cancer drug therapy seems to be necessary, 
i.e. the management may include, in cases of the de-
tection of broad drug resistance, the omission of ag-
gressive  chemotherapy.  This  would  help  to  avoid 
only making sick people sicker. 
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